KR970002876B1 - 피리다지논 유도체 - Google Patents

피리다지논 유도체 Download PDF

Info

Publication number
KR970002876B1
KR970002876B1 KR1019910701537A KR910701537A KR970002876B1 KR 970002876 B1 KR970002876 B1 KR 970002876B1 KR 1019910701537 A KR1019910701537 A KR 1019910701537A KR 910701537 A KR910701537 A KR 910701537A KR 970002876 B1 KR970002876 B1 KR 970002876B1
Authority
KR
South Korea
Prior art keywords
group
straight
alkyl group
branched
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019910701537A
Other languages
English (en)
Korean (ko)
Other versions
KR920701169A (ko
Inventor
게이조 다니까와
아끼라 사이또
다까시 마쓰모또
료조 사꼬다
노부또모 쓰루조에
겐이찌 사까다
Original Assignee
닛산가가꾸고오교 가부시끼가이샤
나까이 다께오
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛산가가꾸고오교 가부시끼가이샤, 나까이 다께오 filed Critical 닛산가가꾸고오교 가부시끼가이샤
Publication of KR920701169A publication Critical patent/KR920701169A/ko
Application granted granted Critical
Publication of KR970002876B1 publication Critical patent/KR970002876B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1019910701537A 1990-04-25 1991-04-19 피리다지논 유도체 Expired - Lifetime KR970002876B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP90-109914 1990-04-25
JP10991490 1990-04-25
PCT/JP1991/000517 WO1991016314A1 (en) 1990-04-25 1991-04-19 Pyridazinone derivative

Publications (2)

Publication Number Publication Date
KR920701169A KR920701169A (ko) 1992-08-11
KR970002876B1 true KR970002876B1 (ko) 1997-03-12

Family

ID=14522343

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701537A Expired - Lifetime KR970002876B1 (ko) 1990-04-25 1991-04-19 피리다지논 유도체

Country Status (17)

Country Link
US (3) US5202323A (enExample)
EP (1) EP0482208B1 (enExample)
JP (1) JPH07107055B2 (enExample)
KR (1) KR970002876B1 (enExample)
AT (1) ATE194835T1 (enExample)
AU (1) AU634655B2 (enExample)
CA (1) CA2053863C (enExample)
DE (1) DE69132329T2 (enExample)
DK (1) DK0482208T3 (enExample)
ES (1) ES2149761T3 (enExample)
GR (1) GR3034331T3 (enExample)
HU (1) HU208124B (enExample)
RU (1) RU2054004C1 (enExample)
TW (1) TW204348B (enExample)
UA (1) UA27031A1 (enExample)
WO (1) WO1991016314A1 (enExample)
ZA (1) ZA913134B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat
US5403590A (en) * 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
JP3080131B2 (ja) 1993-06-29 2000-08-21 日産化学工業株式会社 ピリダジノン誘導体
IL110040A (en) * 1993-06-29 2000-07-16 Nissan Chemical Ind Ltd Pyridazinone derivatives their preparation and pharmaceutical compositions comprising them
EP0717734B1 (en) * 1993-09-06 1998-11-18 Ishihara Sangyo Kaisha, Ltd. Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
TW326041B (en) * 1993-12-16 1998-02-01 Nippon Nouyaku Kk Pyridazinone derivatives, their production process and their use for inhibition of platelet aggregation
US5750523A (en) * 1994-01-25 1998-05-12 Nissan Chemical Industries, Ltd. Pyridazinone derivatives
IL112695A (en) * 1994-02-22 1999-04-11 Green Cross Corp Pharmaceutical compositions containing pyridazinone derivatives
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
US5670504A (en) * 1995-02-23 1997-09-23 Merck & Co. Inc. 2,6-diaryl pyridazinones with immunosuppressant activity
TW434240B (en) * 1995-06-20 2001-05-16 Zeneca Ltd Aromatic compounds, preparation thereof and pharmaceutical composition comprising same
CZ297769B6 (cs) 1996-06-27 2007-03-28 Janssen Pharmaceutica N. V. N-[4-(heteroarylmetyl)fenyl]-heteroarylaminy, zpusob jejich prípravy a jejich pouzití jako léciva
TW482675B (en) * 1997-01-31 2002-04-11 Green Cross Corp Compositions for oral administration containing pyridazinone compounds technical field of the invention
EP1025847B1 (en) 1997-08-28 2005-10-26 Nissan Chemical Industries, Ltd. Neovascularization promoters and neovascularization potentiators
RU2211217C2 (ru) * 1998-06-05 2003-08-27 Эгиш Дьёдьсердьяр Рт. Способ получения 5-хлор-4-аминозамещенного производного 3(2н)-пиридазинона
ATE272401T1 (de) * 1998-09-01 2004-08-15 Nissan Chemical Ind Ltd Heilmittel für die stenose des rückenmarkkanals
UA73104C2 (en) * 1998-12-07 2005-06-15 Nissan Chemical Ind Ltd Erectile dysfunction remedy comprising 3(2h)-pyridazinone derivative
DE20009841U1 (de) * 2000-05-31 2001-10-25 Phyt-Immun GmbH, 66424 Homburg Nasensalbe auf Basis von Vaselin
CA2439593C (en) * 2001-04-05 2010-02-09 Torrent Pharmaceuticals Ltd. Heterocyclic compounds for aging-related and diabetic vascular complications
US20050101631A1 (en) * 2002-08-01 2005-05-12 Otsuka Pharmaceuticals Company Process for producing carbostyril derivatives
US7399864B2 (en) * 2001-05-02 2008-07-15 Otsuka Pharmaceutical Co., Ltd. Process for producing carbostyril derivatives
WO2002094321A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. Compositions for promoting healing of bone fracture
CA2447618A1 (en) 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1913942B1 (en) * 2003-09-09 2009-11-11 Biogen Idec International GmbH The use of fumaric acid derivatives for inhibition of PGF-induced thymidine uptake of bronchial smooth muscle cells and for inhibition of bronchial smooth cells proliferation
KR20060125816A (ko) * 2003-12-26 2006-12-06 닛산 가가쿠 고교 가부시키 가이샤 호중구증다 억제제
RU2339381C2 (ru) * 2004-02-09 2008-11-27 Ниссан Кемикал Индастриз, Лтд. Ингибитор гиперплазии интимы сосудов
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2374805A4 (en) * 2008-12-25 2012-06-27 Nissan Chemical Ind Ltd PYRIDAZINE-3 (2H) -ONE HYDROCHLORIDE COMPOUND CRYSTALS AND METHOD FOR THE PRODUCTION THEREOF
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
TW201130842A (en) * 2009-12-18 2011-09-16 Incyte Corp Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2535048A4 (en) 2010-02-12 2013-08-14 Taisho Pharmaceutical Co Ltd PREPARATION WITH DELAYED RELEASE
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
WO2011163195A1 (en) 2010-06-21 2011-12-29 Incyte Corporation Fused pyrrole derivatives as pi3k inhibitors
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP5961187B2 (ja) 2010-12-20 2016-08-02 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
SI3513793T1 (sl) 2011-09-02 2021-07-30 Incyte Holdings Corporation Heterociklilamini kot zaviralci PI3K
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2014218599C1 (en) 2013-02-25 2018-09-06 Bausch Health Ireland Limited Guanylate cyclase receptor agonists for use in colonic cleansing
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
US20160184387A1 (en) 2013-08-09 2016-06-30 Dominique Charmot Compounds and methods for inhibiting phosphate transport
CA2922943A1 (en) 2013-09-12 2015-03-19 Alios Biopharma, Inc. Pyridazinone compounds and uses thereof
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
MA41607B1 (fr) 2015-02-27 2021-01-29 Incyte Corp Sels d'un inhibiteur de pi3k et procédés de préparation de ces sels
WO2016183063A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Crystalline forms of a pi3k inhibitor
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
CN107793362B (zh) * 2016-08-30 2022-04-22 江苏恩华药业股份有限公司 一种苯基哒嗪酮类衍生物的合成及其应用
BR112020024427A2 (pt) 2018-06-01 2021-03-23 Incyte Corporation regime de dosagem para o tratamento de distúrbios relacionados a pi3k
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2534893A1 (de) * 1975-08-05 1977-02-17 Bayer Ag (thiono)(thiol)pyridazinonalkanphosphonsaeureester, verfahren zu ihrer herstellung sowie ihre verwendung als insektizide und akarizide
CA1265798A (en) * 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
ZW20586A1 (en) * 1985-10-17 1988-05-25 Smith Kline French Lab Chemical compounds
JP2550631B2 (ja) * 1987-01-20 1996-11-06 日産化学工業株式会社 ピリダジノン誘導体
US4978665A (en) * 1987-01-20 1990-12-18 Nissan Chemical Industries Ltd. 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
IE62890B1 (en) * 1988-12-06 1995-03-08 Hafslund Nycomed Pharma New piperazinylalkyl-3(2h)-pyridazinones process for the preparation thereof and the use thereof as agents lowering blood pressure
JPH02256668A (ja) * 1988-12-20 1990-10-17 Nissan Chem Ind Ltd ピリダジノン誘導体
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat

Also Published As

Publication number Publication date
UA27031A1 (uk) 2000-02-28
US5202323A (en) 1993-04-13
CA2053863A1 (en) 1991-10-26
RU2054004C1 (ru) 1996-02-10
TW204348B (enExample) 1993-04-21
US5318968A (en) 1994-06-07
AU634655B2 (en) 1993-02-25
KR920701169A (ko) 1992-08-11
HU913497D0 (en) 1992-01-28
EP0482208A1 (en) 1992-04-29
JPH07107055B2 (ja) 1995-11-15
ES2149761T3 (es) 2000-11-16
HUT60253A (en) 1992-08-28
DE69132329T2 (de) 2000-11-30
ZA913134B (en) 1992-04-29
DK0482208T3 (da) 2000-09-18
WO1991016314A1 (en) 1991-10-31
US5314883A (en) 1994-05-24
CA2053863C (en) 1996-10-29
DE69132329D1 (de) 2000-08-24
HU208124B (en) 1993-08-30
EP0482208A4 (en) 1992-10-07
JPH07107055B1 (enExample) 1995-11-15
ATE194835T1 (de) 2000-08-15
EP0482208B1 (en) 2000-07-19
AU7651191A (en) 1991-11-11
GR3034331T3 (en) 2000-12-29

Similar Documents

Publication Publication Date Title
KR970002876B1 (ko) 피리다지논 유도체
JPWO1991016314A1 (ja) ピリダジノン誘導体
US4978665A (en) 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it
JP3080405B2 (ja) アミノスチルバゾール誘導体及び医薬
JPH06135938A (ja) ３，６−ジ置換ピリダジン誘導体
JPWO1998008836A1 (ja) クロメン−３−カルボン酸誘導体
EP0376079A1 (en) 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A
KR100647726B1 (ko) 피리다진-3-온 유도체 및 이를 함유하는 의약
KR100255416B1 (ko) 약학적 활성을 갖는 피리다지논 유도체
CA1294273C (en) Sulphonamido 3-benzazepine derivatives as antiarrhythmic agents
JP5258763B2 (ja) ５−フェニル−３−ピリダジノン誘導体
US5605901A (en) Indane derivatives, processes for preparing the same and synthetic intermediate of the same
EP0717734B1 (en) Pyridazinone derivatives or their salts, processes for their production, and anti-shock agents containing them
EP0742211B1 (en) Pyridazinone derivatives
TW509692B (en) 2-amino-7-(1-substituted-2-hydroxyethyl)-3,5-dihydro-pyrrolo[3,2-d]pyrimidin-4-ones
WO2003082263A1 (en) Sulfamic acids as inhibitors of human cytoplasmic protein tyrosine phosphatases
FR2711992A1 (fr) Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
US4965266A (en) Heteroarylcarboxamide derivatives, process for preparing the same and pharmaceutical composition containing the same
JPH0578554B2 (enExample)
JP3666042B2 (ja) ピリダジノン誘導体
SU1340587A3 (ru) Способ получени производных конденсированных бензопиронов или их фармацевтически приемлемых солей
JPS63139172A (ja) ４，５−ジヒドロ−６−（６−置換−２−ナフチル）−３（２ｈ）−ピリダジノン誘導体
CA2018956A1 (en) Benzisoquinoline derivatives
JPH068296B2 (ja) アミノクロマノール誘導体
JPH0676390B2 (ja) ピリダジノン誘導体

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19911106

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940609

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19911106

Comment text: Patent Application

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

Comment text: Decision on Publication of Application

Patent event code: PG16051S01I

Patent event date: 19970213

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970530

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19970822

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19970822

End annual number: 3

Start annual number: 1

PR1001 Payment of annual fee

Payment date: 20000229

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20010816

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20020806

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20030806

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20040809

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20050809

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20060810

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20070808

Start annual number: 11

End annual number: 11

PR1001 Payment of annual fee

Payment date: 20080808

Start annual number: 12

End annual number: 12

PR1001 Payment of annual fee

Payment date: 20090807

Start annual number: 13

End annual number: 13

FPAY Annual fee payment

Payment date: 20100811

Year of fee payment: 14

PR1001 Payment of annual fee

Payment date: 20100811

Start annual number: 14

End annual number: 14

EXPY Expiration of term
PC1801 Expiration of term